Baseline demographics and clinical characteristics of the study population (n = 80).
| Demographic characteristics (n = 80) . | |
|---|---|
| Age | 34.35 ± 6.96 |
| Sexual activity | 60 (75%) |
| Smoking | 23 (28.75%) |
| Body mass index (kg/m2) | 22.21 ± 2.75 |
| <18.5 | 1 (1.25%) |
| 18.5–24.9 | 68 (85%) |
| 25–29.9 | 11 (13.75%) |
| Contraceptive use | 49 (61.25%) |
| Oral | 15 (30.61%) |
| Barrier | 16 (32.65%) |
| Others | 18 (36.74%) |
| Clinical characteristics (n = 80) | |
| Vulvovaginal signs and symptoms | |
| Leucorrhoea | 80 (100%) |
| Burning | 30 (37.50%) |
| Itching | 37 (46.25%) |
| Subjective vulvar discomfort | 80 (100%) |
| Amsel Criteria | |
| Homogenous vaginal discharge | 79 (98.75%) |
| Clue cell presence | 75 (93.75%) |
| Positive amine test | 78 (97.50%) |
| Vaginal pH > 4.5 | 77 (96.25%) |
| Nugent score | |
| 0–3 | 0 (0%) |
| 4–6 | 1 (1.25%) |
| 7–10 | 79 (98.75%) |
| Lactobacillary grade | |
| I | 0 (0%) |
| II | 36 (45%) |
| III | 44 (55%) |
| Demographic characteristics (n = 80) . | |
|---|---|
| Age | 34.35 ± 6.96 |
| Sexual activity | 60 (75%) |
| Smoking | 23 (28.75%) |
| Body mass index (kg/m2) | 22.21 ± 2.75 |
| <18.5 | 1 (1.25%) |
| 18.5–24.9 | 68 (85%) |
| 25–29.9 | 11 (13.75%) |
| Contraceptive use | 49 (61.25%) |
| Oral | 15 (30.61%) |
| Barrier | 16 (32.65%) |
| Others | 18 (36.74%) |
| Clinical characteristics (n = 80) | |
| Vulvovaginal signs and symptoms | |
| Leucorrhoea | 80 (100%) |
| Burning | 30 (37.50%) |
| Itching | 37 (46.25%) |
| Subjective vulvar discomfort | 80 (100%) |
| Amsel Criteria | |
| Homogenous vaginal discharge | 79 (98.75%) |
| Clue cell presence | 75 (93.75%) |
| Positive amine test | 78 (97.50%) |
| Vaginal pH > 4.5 | 77 (96.25%) |
| Nugent score | |
| 0–3 | 0 (0%) |
| 4–6 | 1 (1.25%) |
| 7–10 | 79 (98.75%) |
| Lactobacillary grade | |
| I | 0 (0%) |
| II | 36 (45%) |
| III | 44 (55%) |
Baseline demographics and clinical characteristics of the study population (n = 80).
| Demographic characteristics (n = 80) . | |
|---|---|
| Age | 34.35 ± 6.96 |
| Sexual activity | 60 (75%) |
| Smoking | 23 (28.75%) |
| Body mass index (kg/m2) | 22.21 ± 2.75 |
| <18.5 | 1 (1.25%) |
| 18.5–24.9 | 68 (85%) |
| 25–29.9 | 11 (13.75%) |
| Contraceptive use | 49 (61.25%) |
| Oral | 15 (30.61%) |
| Barrier | 16 (32.65%) |
| Others | 18 (36.74%) |
| Clinical characteristics (n = 80) | |
| Vulvovaginal signs and symptoms | |
| Leucorrhoea | 80 (100%) |
| Burning | 30 (37.50%) |
| Itching | 37 (46.25%) |
| Subjective vulvar discomfort | 80 (100%) |
| Amsel Criteria | |
| Homogenous vaginal discharge | 79 (98.75%) |
| Clue cell presence | 75 (93.75%) |
| Positive amine test | 78 (97.50%) |
| Vaginal pH > 4.5 | 77 (96.25%) |
| Nugent score | |
| 0–3 | 0 (0%) |
| 4–6 | 1 (1.25%) |
| 7–10 | 79 (98.75%) |
| Lactobacillary grade | |
| I | 0 (0%) |
| II | 36 (45%) |
| III | 44 (55%) |
| Demographic characteristics (n = 80) . | |
|---|---|
| Age | 34.35 ± 6.96 |
| Sexual activity | 60 (75%) |
| Smoking | 23 (28.75%) |
| Body mass index (kg/m2) | 22.21 ± 2.75 |
| <18.5 | 1 (1.25%) |
| 18.5–24.9 | 68 (85%) |
| 25–29.9 | 11 (13.75%) |
| Contraceptive use | 49 (61.25%) |
| Oral | 15 (30.61%) |
| Barrier | 16 (32.65%) |
| Others | 18 (36.74%) |
| Clinical characteristics (n = 80) | |
| Vulvovaginal signs and symptoms | |
| Leucorrhoea | 80 (100%) |
| Burning | 30 (37.50%) |
| Itching | 37 (46.25%) |
| Subjective vulvar discomfort | 80 (100%) |
| Amsel Criteria | |
| Homogenous vaginal discharge | 79 (98.75%) |
| Clue cell presence | 75 (93.75%) |
| Positive amine test | 78 (97.50%) |
| Vaginal pH > 4.5 | 77 (96.25%) |
| Nugent score | |
| 0–3 | 0 (0%) |
| 4–6 | 1 (1.25%) |
| 7–10 | 79 (98.75%) |
| Lactobacillary grade | |
| I | 0 (0%) |
| II | 36 (45%) |
| III | 44 (55%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
